Daptomycin has demonstrated potent in vitro activity against many common staphylococci and streptococci, such as Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]; MIC 90 , 0.5 g/ml), coagulase-negative staphylococci (Staphylococcus epidermidis [MIC 90 , 0.5 g/ml] and less frequently isolated species), group A and B ␤-hemolytic streptococci (MIC 90 , Յ0.03 g/ml), Enterococcus faecalis (MIC 90 , 1 g/ml), and Enterococcus faecium (MIC 90 , 2 g/ml), in numerous investigations (4, 5). However, limited information exists on the activity of daptomycin tested against less frequently isolated Gram-positive species. We evaluated daptomycin activity tested against uncommonly isolated streptococci and three other Gram-positive groups derived from recent global surveillance programs.
D
aptomycin is a natural cyclic lipopeptide with rapid in vitro bactericidal activity against a wide spectrum of Gram-positive organisms. Daptomycin was initially approved by the U.S. Daptomycin has demonstrated potent in vitro activity against many common staphylococci and streptococci, such as Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA] ; MIC 90 , 0.5 g/ml), coagulase-negative staphylococci (Staphylococcus epidermidis [MIC 90 , 0.5 g/ml] and less frequently isolated species), group A and B ␤-hemolytic streptococci (MIC 90 , Յ0.03 g/ml), Enterococcus faecalis (MIC 90 , 1 g/ml), and Enterococcus faecium (MIC 90 , 2 g/ml), in numerous investigations (4, 5) . However, limited information exists on the activity of daptomycin tested against less frequently isolated Gram-positive species. We evaluated daptomycin activity tested against uncommonly isolated streptococci and three other Gram-positive groups derived from recent global surveillance programs. The majority of isolates were from 77 U.S. medical centers, whereas four less common species isolates were obtained from worldwide hospital locations, including Streptococcus equisimilis, Streptococcus mutans, Corynebacterium spp., and L. monocytogenes.
Daptomycin and comparators were tested for susceptibility by the reference Clinical and Laboratory Standards Institute (CLSI) broth microdilution method (6, 7). The cation-adjusted MuellerHinton broth was supplemented with 2.5 to 5% lysed horse blood when fastidious streptococcal species were tested. Also, the test medium was adjusted to contain physiological levels of calcium (50 mg/liter) when daptomycin was tested (6) . All quality control results were within published ranges for daptomycin when S. aureus ATCC 29213 and E. faecalis ATCC 29212 were tested (7) .
Daptomycin exhibited potent in vitro activity when tested against seven groups of viridans group streptococci tested with MIC 50 and MIC 90 results ranging from Յ0.06 and Յ0.06 g/ml (Streptococcus bovis and Streptococcus dysgalactiae groups) to 0.5 and 1 g/ml (Streptococcus mitis, Streptococcus oralis, and Streptococcus parasanguinis), respectively ( Table 1 ). The highest daptomycin MIC value among viridans group streptococci was 2 g/ml, which was observed in only two strains (0.3%): one Streptococcus anginosus strain and one S. oralis strain (Table 1) .
Daptomycin was highly active against ␤-hemolytic streptococci serogroups C (MIC 50 and MIC 90 , Յ0.06 and 0.25 g/ml, respectively), F (MIC 50 and MIC 90 , 0.25 and 0.25 g/ml, respectively), and G (MIC 50 and MIC 90 , Յ0.06 and 0.12 g/ml, respectively). The highest daptomycin MIC value among ␤-hemolytic streptococci was only 0.5 g/ml (Table 1) . Daptomycin MIC results were slightly lower among ␤-hemolytic streptococci serogroups G and C (MIC 50 , Յ0.06 g/ml for both groups) than among serogroup F (MIC 50 , 0.25 g/ml) ( (Table 1) . Although uncommonly isolated in the clinical microbiology laboratory, the organisms evaluated in the present study may cause life-threatening infections, and limited data about their antimicrobial susceptibility patterns are available to guide therapy. Viridans group Streptococcus spp. represent a major cause of endocarditis as well as bacteremia with septic shock in neutropenic patients (8) , whereas serogroup C, F, and G beta-hemolytic streptococci can cause a wide array of infections, including upper respiratory tract infections, skin and soft tissue infections, necrotizing fasciitis, bacteremia, and endocarditis (9) . Corynebacterium spp. are increasingly being recognized as causing opportunistic disease under specific circumstances, such as in patients who are immunocompromised, have prosthetic devices, or have been in hospitals/nursing homes for long periods of time (10) . Micrococcus spp. are usually acknowledged as nonpathogenic, commensal microorganisms but can also act as opportunistic pathogens and may cause valve endocarditis, folliculitis, bacteremia, meningitis, pneumonia, and even fatal infections as nosocomial pathogens (11) . Lastly, Listeria spp. are also considered opportunistic pathogens, and the majority of listeriosis cases occur among individuals with underlying conditions that lead to suppression of cell-mediated immunity; however, epidemic common-source infections in immunocompetent individuals are increasingly being reported (12) .
These daptomycin susceptibility results presented here document the wider potential clinical application to uncommonly isolated Gram-positive species. The results of this study coupled with documented daptomycin clinical efficacy and safety experience in the treatment of severe staphylococcal infections, including bacteremia and endocarditis (2, 3), indicate that this antimicrobial represents a valuable option for treatment of infections caused by a wide variety of Gram-positive species as guided by reference MIC test results and/or published surveillance literature.
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